Cue Biopharma (CUE) Expected earnings per share growth for next year

Corporate company logo of Cue Biopharma (CUE)

The expected annual EPS growth rate for the coming year demonstrates the implementation of AI and robotics to automate the creation of biologics for Cue Biopharma, Inc. (CUE). Current R&D expenditures for T-cell modulation are covered through partnerships amid a gradual capital burn. The 69.70 level serves as a critical mark, as the company's success relies on patent protection and the clinical trial results of its oncology drugs.

Cue Biopharma (CUE): Projected earnings per share growth rate for next year from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Cue Biopharma, Inc. (CUE)

- price and consensus price forecast:
Fundamental valuation:Cue Biopharma, Inc., CUE
Brand item of Cue Biopharma Inc.

This indicator reflects the consensus forecast for earnings per share growth rates in the next period, measuring market expectations regarding future business monetization. By analyzing changes in analyst expectations for EPS n+1 growth, an investor can identify asset revaluation phases prior to a potential acquisition. For Cue Biopharma, Inc. (CUE), this trend correlates directly with the commercial success of the Immuno-STAT platform for targeted T-cell activation.

Competitor analysis for Cue Biopharma, Inc.

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Corp TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (immatics.com) - Projected earnings per share growth rate for next year|Xencor Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Compass Bio (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year IPHA (Innate Pharma, S.A.)|Projected earnings per share increase next year PYXS|Earnings growth forecast for next year CGEN (Compugen Ltd.)|Expected earnings per share trend next year IOBT|sutrobio.com - Earnings growth forecast for next year|Expected net earnings per share growth next year MiNK Therapeutics, Inc|Werewolf (HOWL) - Net earnings per share growth forecast for next year|Immix Biopharma Inc. - Expected earnings per share trend next year|ALXO (alxoncology.com) - Earnings growth forecast for next year|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year